Form 4: Kiromic Biopharma Director Pamela Misajon Reports Transaction
SEC Form 4 Filing
Pamela Misajon, a director at Kiromic Biopharma, reported a transaction involving the company's common stock on June 10, 2024.
Summary
- On June 10, 2024, Pamela Misajon, a director of Kiromic Biopharma, engaged in a transaction involving the company's common stock.
- Misajon acquired 1,701 shares of common stock at a price of $2.93 per share.
- Following the reported transaction, Misajon directly owns 27,201 shares of Kiromic Biopharma.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting a transaction by a company director, indicating a neutral sentiment.
Industry Context
This filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities.
Stakeholder Impact
- The transaction provides shareholders with insight into the actions of a company director.
Key Dates
| Date | Description |
|---|---|
| 06/10/2024 | Date of the stock transaction. |
| 06/12/2024 | Date of signature for the Form 4 filing. |
Keywords
Kiromic Biopharma, KRBP, Pamela Misajon, Director, Stock Transaction, Form 4, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.